BRIEF-JCR Pharmaceuticals Announces Licensing Agreement With Menagen To Commercialize Agalsidase Beta BS I.V. Infusion

Oct 1 (Reuters) – JCR Pharmaceuticals Co Ltd: * JCR PHARMACEUTICALS ANNOUNCES LICENSING AGREEMENT WITH MENAGEN TO COMMERCIALIZE AGALSIDASE BETA BS I.V. INFUSION ACROSS NINE MENAT MARKETS * JCR PHARMACEUTICALS CO LTD: DOES NOT EXPECT A MATERIAL IMPACT ON FY2025 CONSOLIDATED RESULTS FROM MENAGEN DEAL Source text: Further company coverage: ;))

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)